Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has provided a recap of its 2021 milestones and highlights as the company expands its portfolio of next-generation psychedelic compounds.
In a statement, Mindset CEO James Lanthier called 2021 “just the beginning” for the company.
“We are building the industry’s leading drug discovery platform and intend to continue to break new ground in psychedelic drug discovery in order to bring patented, safe and effective therapies to those suffering from a range of mental illnesses and neurological disorders.
“In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies,” Lanthier said.
READ: Mindset Pharma files international patent application covering its Family 3 psychedelic compounds
He added: “As we enter 2022, we are excited to advance these novel therapies towards the clinic as we progress IND-enabling studies for our lead candidate, MSP-1014, and select additional candidates from our other families of compounds.”
Operational highlights in 2021 included:
- Expanded Patent Portfolio: Filed four provisional patent applications bringing the total to eight provisional applications filed to date. Mindset also has filed four final PCT applications, which cover a broad range of novel, next-generation drugs inspired by psilocybin, DMT, 5-MeO-DMT, and a novel psilocybin synthesis and manufacturing method
- Advanced First Lead Drug Candidate Toward Clinical Trials: Selected its first lead clinical candidate, MSP-1014, a differentiated psilocybin-based analog, to move forward into investigational new drug (IND) enabling studies
- Growing Library of Novel Compounds: Synthesized over 100 novel compounds in more than 500 in vitro and in vivo studies
- Developed First-in-Class Benchmarking: Under the Cooperative Psychedelics Evaluation Platform (COPE) program, Mindset and partner InterVivo Solutions continued to develop first-in-class benchmarking data across first-generation psychedelic drugs
- Effect Size & Safety Differentiation Driven by Technology Platform: Preclinical data generated across the four families of novel chemical entities resulted in the identification of a platform technology that enhances effect size and improves safety profiles of psychedelic drugs. A provisional patent application was filed in May of 2021
- Enhanced Leadership and Advisory Teams: Appointed Dr. Malik Slassi as senior vice president of innovation, Ian Dean as director of preclinical development, and Drs. Michael Rogawski, Guy Higgins, Joseph Gabriele, and Ishrat Husain to its Scientific Advisory Board
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham